Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Glucopyranosyl Lipid A (GLA)
Glucopyranosyl Lipid A · 1 trial · 1 indication
Number of participants with AEs
| Arm | Type | Description |
|---|---|---|
| SAR439794 [PE SLIT + GLA)] | EXPERIMENTAL | GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks |
| Placebo for GLA + SLIT PE | EXPERIMENTAL | Placebo for GLA repeated doses then SLIT PE escalating doses once daily for 12 weeks |
| Placebo for GLA + Placebo for SLIT PE | PLACEBO_COMPARATOR | Placebo for GLA repeated doses then Placebo for SLIT PE escalating doses once daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| Glucopyranosyl Lipid A (GLA) | DRUG | Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual |
| Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) | DRUG | Pharmaceutical form:Solution Route of administration: Sublingual |
| Placebo for GLA | DRUG | Pharmaceutical form:Colloidal aqueous dispersion Route of administration: Sublingual |
| Placebo for SLIT PE | DRUG | Pharmaceutical form:Solution Route of administration: Sublingual |
Inclusion criteria : * Male or female patients, between 18 and 55 years of age, inclusive and adolescents between 12 and 17 years of age (after enrollment of 20 adult patients completed the 6 weeks dose escalation period and the safety and tolerability is deemed acceptable). * Physician-diagnosed p...
Glucopyranosyl Lipid A is being studied for the treatment of food allergy, specifically peanut allergy. It was evaluated in a Phase 1 clinical trial in peanut allergic adult and adolescent patients. It is an investigational agent and is not approved for any indication.
Glucopyranosyl Lipid A is being developed by Sanofi, which trades under the ticker SNY. The company sponsored the Phase 1 study of the agent in peanut allergic patients.
Glucopyranosyl Lipid A is in Phase 1 clinical development. The single Phase 1 trial has been completed, and no active trials are currently listed. It remains an investigational agent and has not been approved by the FDA.
Glucopyranosyl Lipid A has been evaluated in one completed Phase 1 trial, NCT03463135. The study assessed the tolerability and safety of repeated sublingual daily administration of SAR439794 in peanut allergic adult and adolescent patients, enrolling 27 participants in the United States.
Yes, Glucopyranosyl Lipid A is also known as GLA. The abbreviation GLA refers to the same investigational agent being developed by Sanofi for food allergy.